Final draft guidance published by Nice shows NHS England requested that Mounjaro is rolled out over a period of 12 years. The watchdog recommends prioritising patients receiving care from specialist ...
Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...
The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...
Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel full for ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
“Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication ... Wegovy ...
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the ...
Enveda’s pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback